ÖZGÜROĞLU, M. Et Al. 2023. Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , (Illinois, United States Of America).

ÖZGÜROĞLU, M., Levy, B. P., Horinouchi, H., Yu, J., Grainger, E., Phuong, P. H., ... Peterson, D.(2023). Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8). . Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America

ÖZGÜROĞLU, MUSTAFA Et Al. "Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).," Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2023

ÖZGÜROĞLU, MUSTAFA Et Al. "Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America, 2023

ÖZGÜROĞLU, M. Et Al. (2023) . "Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , Illinois, United States Of America.

@conferencepaper{conferencepaper, author={MUSTAFA ÖZGÜROĞLU Et Al. }, title={Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).}, congress name={Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)}, city={Illinois}, country={United States Of America}, year={2023}}